Vir Biotechnology and Gilead Sciences have agreed to develop three dual-masked T-cell engager programmes under a deal worth up to approximately $1.88 billion. The $90 million upfront package includes cash and equity, while most of the headline value depends on future development and commercial milestones.
Lux Infusion adds Sanofi's Qfitlia to its hemophilia services, combining specialty pharmacy access with insurance and clinical support.
Sanofi plans to transfer 20 mature medicines and manufacturing facilities in France, Hungary and Singapore to Cheplapharm while taking a 26.4% stake in the specialist pharmaceutical company.
Kali Therapeutics has received FDA IND clearance for KT501, a CD19xBCMAxCD3 trispecific T-cell engager designed to produce deep B-cell and plasma-cell depletion in autoimmune disease.
Remibrutinib wins two Phase III multiple sclerosis trials as Novartis prepares global filings. See what the results mean for the BTK race.
miRecule and Rio Biofarma are pairing peptide delivery with RNA payloads, but clinical validation and scalable manufacturing remain ahead.
The United States Food and Drug Administration (FDA) has approved Sanofi’s Sarclisa Escena for subcutaneous administration through the CirCLIQ on-body injector, creating the first FDA-authorised anticancer treatment that can be delivered using a wearable injector. The regulator approved the fixed 1,400-milligram dose on July 9, 2026 for several multiple myeloma treatment combinations already supported by
Discover how wearable injectors could reshape multiple myeloma treatment, clinic capacity and the competitive battle between Sarclisa and daratumumab.
Find out how Sanofi’s Sarclisa SC approval in Japan could change multiple myeloma treatment delivery and strengthen its oncology strategy today!
Discover how Sanofi’s Tzield approval could reshape newly diagnosed pediatric type 1 diabetes care and why major clinical questions remain.